We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
+13.82%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$1.4B
AUM Growth
+$48.4M
Cap. Flow
+$26.9M
Cap. Flow %
1.92%
Top 10 Hldgs %
65.74%
Holding
68
New
19
Increased
7
Reduced
4
Closed
19

Top Buys

Rank Stock Value
1
RLAY icon
Relay Therapeutics
RLAY
+$122M
2
NRIX icon
Nurix Therapeutics
NRIX
+$30M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$14.6M
4
BCEL
Atreca, Inc. Class A Common Stock
BCEL
+$14M
5
KLRS
Kalaris Therapeutics
KLRS
+$13.3M

Top Sells

Rank Stock Value
1
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$69.1M
2
RARE icon
Ultragenyx Pharmaceutical
RARE
+$40.6M
3
FATE icon
Fate Therapeutics
FATE
+$21.3M
4
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$20.5M
5
DNLI icon
Denali Therapeutics
DNLI
+$17.7M

Sector Composition

Rank Sector Weight
1 Healthcare 95.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRVS icon
51
Corvus Pharmaceuticals
CRVS
$1.1B
– –
-737,612
Closed -$2.01M
DNLI icon
52
Denali Therapeutics
DNLI
$3.79B
– –
-733,561
Closed -$17.7M
DNTH icon
53
Dianthus Therapeutics
DNTH
$5.69B
– –
-28,125
Closed -$3.38M
EQ icon
54
Equillium
EQ
$144M
– –
-59,014
Closed -$174K
FATE icon
55
Fate Therapeutics
FATE
$275M
– –
-619,855
Closed -$21.3M
FULC icon
56
Fulcrum Therapeutics
FULC
$241M
– –
-882,353
Closed -$16.1M
KROS icon
57
Keros Therapeutics
KROS
$197M
– –
-220,216
Closed -$8.26M
PLRX icon
58
Pliant Therapeutics
PLRX
$65M
– –
-1,300
Closed -$42K
RARE icon
59
Ultragenyx Pharmaceutical
RARE
$2.46B
– –
-519,119
Closed -$40.6M
RLMD icon
60
Relmada Therapeutics
RLMD
$540M
– –
-200,000
Closed -$8.95M
EVLO
61
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
– –
-62,500
Closed -$6.13M
KLDO
62
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
– –
-31,374
Closed -$233K
DRNA
63
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
– –
-2,721,993
Closed -$69.1M
CNST
64
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
– –
-837,885
Closed -$20.5M
PRVL
65
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
– –
-367,218
Closed -$5.47M
BMY.RT
66
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
– –
-4,748,300
Closed -$17M
LSACU
67
DELISTED
LifeSci Acquisition Corp. Unit 1 COM & 1 WT
LSACU
– –
-300,000
Closed -$3.3M
1 2
3

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
CIP
Cornerstone Investment Partners Atlanta, Georgia $2.38B AUM 32.49% 1-Year Est. Return

EcoR1 Capital's Q3 2020 Portfolio in Review

As of Q3 2020, EcoR1 Capital held 68 positions worth $1.4B, up 3.6% from $1.35B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

EcoR1 Capital's Q3 2020 filing shows 19 new, 7 increased, 4 reduced and 19 closed positions. Its largest new stake was Relay Therapeutics: 3,200,649 shares worth $136M. The largest sale was Dicerna Pharmaceuticals, Inc., an estimated $69.1M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 92% a quarter earlier.

  • EcoR1 Capital's largest Q3 2020 buy was Relay Therapeutics: 3,200,649 shares worth $136M.
  • EcoR1 Capital added most to Mirati Therapeutics, Inc. Common Stock in Q3 2020, an estimated $14.6M increase.
  • EcoR1 Capital's biggest Q3 2020 reduction was Assembly Biosciences, cutting an estimated $12.7M.
  • EcoR1 Capital fully exited Dicerna Pharmaceuticals, Inc. in Q3 2020, selling an estimated $69.1M.
  • EcoR1 Capital's ten largest holdings make up 66% of its $1.4B portfolio in Q3 2020.
  • EcoR1 Capital opened 19 new positions and closed 19 in Q3 2020.
  • EcoR1 Capital's portfolio value rose 3.6% quarter-over-quarter to $1.4B.

Based on EcoR1 Capital's 13F filing for Q3 2020, filed 16 Nov 2020.